The inflammation-based Glasgow prognostic score predicts poor survival in advanced stage epithelial ovarian cancer

2015 ◽  
Vol 139 (1) ◽  
pp. 192
Author(s):  
H. Chang ◽  
M. Holzapfel ◽  
C. Walsh ◽  
A.J. Li
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Advanced Stage ◽  
Poor Survival

scholarly journals Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer

2016 ◽  
Vol 5 (6) ◽  
pp. 1074-1080 ◽  
Author(s):  
Chiaki Omichi ◽  
Keiichiro Nakamura ◽  
Junko Haraga ◽  
Hisashi Masuyama ◽  
Yuji Hiramatsu
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Poor Prognosis ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Independent Marker

scholarly journals Hubungan antara Modified Glasgow Prognostic Score (mGPS) dengan Stadium dan Derajat Diferensiasi Kanker Ovarium

2021 ◽  
Vol 7 (3) ◽  
pp. 160
Author(s):  
Bob Irsan ◽  
Heru Pradjatmo ◽  
Muhammad Lutfi
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Residual Tumor ◽  
Albumin Level ◽  
Surgical Staging ◽  
Chemotherapy Response ◽  
Cross Sectional ◽  
Cancer Data

Background: Prognostic factors for ovarian cancer include residual tumor and chemotherapy response, but these parameters are not sufficient to predict ovarian cancer prognoses. A new approach such as mGPS that use a combination of CRP and albumin can be used to assess an inflammatory response. With mGPS, an elevated CRP value and hypoalbuminemia are poor prognosis. Objective: To investigate the effect of mGPS on histopathologic staging and grading of ovarian cancer.Method: The study design was a cross sectional study. The population of this study were patients with suspected ovarian cancer who underwent laparotomy surgical staging at RSUP Dr. Sardjito. The samples were patients with suspected ovarian cancer that have examined the hs-CRP level and albumin level preoperative,then underwent laparotomy surgical staging with histopathological results epithelial ovarian cancer. Data were analyzed using Chi Square test and logistic regression.Results and Discussion: there were 57 subjects with epithelial ovarian cancer consisting of 25 subjects (43.86%) with high mGPS and 32 subjects (56.14%) with low mGPS. The value of mGPS is associated with the stage of ovarian cancer (p = 0.000; RP = 4.000 CI 95% = 2.195 – 7.289). The results of the multivariate analysis showed that the most important factor in determining the stage was mGPS (p = 0.000; RP = 3.818 95% CI = 1.544-6.092). While the most important factor in determining histopathologic grading of ovarian cancer was the type of ovarian tumor (p = 0.000; RP = 7.339 95% CI = 4.960-9.718).Conclusion: There was an association between mGPS and the stage of ovarian cancer. The histopathologic grading was not influenced by mGPS, but was influenced by the type of ovarian tumor.Keywords: mGPS; Stage; Histopathologic grading; Ovarian Cancer; Epithelial Type

scholarly journals Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group

2021 ◽  
Vol 10 (5) ◽  
pp. 1058
Author(s):  
Grégoire Rocher ◽  
Thomas Gaillard ◽  
Catherine Uzan ◽  
Pierre Collinet ◽  
Pierre-Adrien Bolze ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Retrospective Cohort ◽  
Early Stage ◽  
Cohort Analysis ◽  
Recurrence Free Survival ◽  
Advanced Stage ◽  
Free Survival ◽  
Retrospective Cohort Analysis

To determine if the time-to-chemotherapy (TTC) after primary macroscopic complete cytoreductive surgery (CRS) influences recurrence-free survival (RFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC). We conducted an observational multicenter retrospective cohort analysis of women with EOC treated from September 2006 to November 2016 in nine institutions in France (FRANCOGYN research group) with maintained EOC databases. We included women with EOC (all FIGO stages) who underwent primary complete macroscopic CRS prior to platinum-based adjuvant chemotherapy. Two hundred thirty-three patients were included: 73 (31.3%) in the early-stage group (ESG) (FIGO I-II), and 160 (68.7%) in the advanced-stage group (ASG) (FIGO III-IV). Median TTC was 43 days (36–56). The median OS was 77.2 months (65.9–106.6). OS was lower in the ASG when TTC exceeded 8 weeks (70.5 vs. 59.3 months, p = 0.04). No impact on OS was found when TTC was below or above 6 weeks (78.5 and 66.8 months, respectively, p = 0.25). In the whole population, TTC had no impact on RFS or OS. None of the factors studied were associated with an increase in TTC. Chemotherapy should be initiated as soon as possible after CRS. A TTC greater than 8 weeks is associated with poorer OS in patients with advanced stage EOC.

scholarly journals Phosphatase Regenerating Liver3 and ECadherin Expression in Epithelial Ovarian Cancer

2017 ◽  
pp. 170-175
Author(s):  
Risma Maharani ◽  
Syahrul Rauf ◽  
Rina Masadah
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Early Stage ◽  
Cross Sectional Study ◽  
Teaching Hospitals ◽  
Advanced Stage ◽  
Cross Sectional ◽  
Exact Test ◽  
Significant Difference ◽  
E Cadherin

Objective: To determine the expression of Phosphatase Regenerating Liver-3 (PRL-3) and E-Cadherin in the epithelial ovarian cancer on various stages and differentiation grades. Method: This was a cross-sectional study design conducted at Obstetrics and Gynecology Department of several teaching hospitals, Faculty of Medicine Universitas Hasanuddin from January to June 2015. The expression of PRL-3 and E-cadherin was assessed immunohistochemically in 40 patients with epithelial ovarian cancer including 15 patients in early stage and 25 patients in advanced stage. We used the Fisher’s exact test with the significance of p0.05). The significant difference was found in the expression of E-cadherin whereas the high expression was shown at early stage than advanced stage (p0.05). This study also pointed out no correlation between the expression of PRL-3 and E-cadherin in epithelial ovarian cancer (p>0.05). Conclusion: PRL-3 overexpression does not decrease E-cadherin expression in epithelial ovarian cancer. Keywords: E-cadherin, epithelial ovarian cancer, PRL-3

Sign in / Sign up

Export Citation Format

Share Document